Introduction
Although systemic (arterial) hypertension results in high intravascular pressure, the main complications of hypertension, that is, coronary heart disease (CHD), ischaemic strokes and peripheral vascular disease (PVD), are related to thrombosis rather than haemorrhage. The association between hypertension and risk for stroke and CHD almost appears to have a dose-response relationship, with increasing risk for higher blood pressures (BP). [1] [2] [3] Indeed an increase in the diastolic blood pressure (DBP) by 10 mmHg is associated with an increase in CHD risk by one-third and stroke by more than half. [1] [2] [3] In middle and old age, there appears to be a direct relationship between the level of BP and the risk of cardiovascular death without any evidence of a threshold down to a BP of at least 115/75 mmHg. 4 Correspondingly, BP reduction trials have shown a reduction in CHD by 16% and stroke by 38%. It should not be forgotten that hypertension is a risk factor for both haemorrhagic as well as ischaemic strokes.
It should be recognised that some of the complications related to hypertension, such as heart failure or atrial fibrillation, are themselves associated with stroke and thromboembolism. 5 Increasing evidence also points towards a prothrombotic or hypercoagulable state conferred by the presence of hypertension, as evident by abnormalities of coagulation, 6, 7 platelets 6, 7 and endothelial function [8] [9] [10] in such patients. It therefore seems plausible that use of antithrombotic therapy may help to prevent thrombosis-related complications of hypertension. 5 The antithrombotic agent, aspirin, has long been used in the treatment and secondary prevention of many of the complications of hypertension, but until recently little information has been available on its role in the management of asymptomatic, hypertensive individual. Warfarin has also been found to be useful as thromboprophylaxis in hypertensive patients with atrial fibrillation, 11, 12 but if blood pressures remain uncontrolled, such therapy carries significant risks, especially from intracranial haemorrhage.
Objectives
A systematic review of the role of antiplatelet therapy and anticoagulation was conducted in patients with systemic (arterial) hypertension, including those with systodiastolic hypertension, isolated systolic hypertension and diastolic hypertension, to address the following hypotheses: (i) antiplatelet agents reduce total deaths and/or major thrombotic events in patients when compared to placebo or other active treatment; and (ii) oral anticoagulants reduce total deaths and/or major thromboembolic events in patients with hypertension when compared to placebo or other active treatment.
It should be noted that antithrombotic therapy in atrial fibrillation 11 and heart failure 13 per se are considered in detail in separate Cochrane reviews. In atrial fibrillation, for example, the presence of hypertension increases the risk of stroke and thromboembolism, and such patients are at moderate-to-high risk; hypertension and atrial fibrillation also commonly coexist.
Methods
Criteria for considering studies for this review (a) Types of studies Single-or double-blind randomised controlled trials comparing antiplatelet drugs or oral anticoagulation with control or active treatment were included. Cohort-studies, nonrandomised controlled studies, and open-label studies were excluded.
(b) Types of participants Patients with at least mild hypertension or isolated systolic or diastolic hypertension as defined (for practical reasons) by the WHO-ISH Guidelines for Management of Hypertension 1999 and/or British Society of Hypertension Guidelines for Management of Hypertension 1999 14, 15 were included. In trials prior to 1999, WHO-ISH guidelines valid at the time of the study/publication were used. 16 Generally, a systolic blood pressure (SBP) of X160 mmHg and/or a DBP of X100 mmHg was considered to be elevated and fit the criteria. Patients with atrial fibrillation, congestive heart failure, pre-eclampsia, eclampsia or pulmonary hypertension were excluded.
(c) Types of interventions Treatment duration of at least 3 months with antiplatelet agents (aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), dipyridamole, clopidogrel, glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa inhibitors) (ie ticlopidine)) or oral anticoagulants (warfarin and other vitamin K antagonist anticoagulants) were included. Available data on concomitant treatment were collected, where available.
Types of outcome measures
(a) Primary outcome measure(s) All cause mortality and cardiovascular mortality (stroke, myocardial infarction, sudden death, thromboembolic events).
(b) Secondary outcome measure(s) All nonfatal cardiovascular events (stroke, myocardial infarction, thromboembolic events such as acute coronary syndrome, acute limb ischaemia, pulmonary embolism, deep vein thrombosis), as a composite end point. All major bleeding events (fatal, nonfatal) as a composite end point. A major bleed was defined as haemorrhagic stroke, or major blood loss defined as a drop in haemoglobin of 42 g/dl with adequate hydration, or urgent transfusion with final haemoglobin after equilibration of less than prebleed level, or orthostatic hypotension, or supine blood pressure under 90/60 mmHg.
(c) Tertiary outcome measure(s) All cardiovascular events (sudden death, fatal, nonfatal: stroke, myocardial infarction, thromboembolic events, coronary revascularisation) as a composite end point. Any interaction between risk factors for cardiovascular disease or bleeding, and concomitant treatment were analysed if appropriate data were available. Further details will be obtained from trial authors, if possible.
The search strategy for identification of studies is summarised in Table 1 (also see Collaborative Review Group Research Strategy 17 ).
Methods of the review
Two reviewers (GYHL and DCF), independently, selected suitable trials for the inclusion of the review. There was a review of the inclusion criteria for each question, the search strategies, the methodology criteria, and methods for pooling the data. Nonrandomised studies would not usually be helpful in a review of the effects of these drugs as any estimates of treatment effects are likely to be biased, but they have been included as they may help in assessing side effects in the case of anticoagulants. Assessment of trial quality will be made in accor-dance with guidelines in the Cochrane Handbook, 18 with consideration of adequacy of randomisation, degree of blinding, and losses to follow-up for each trial.
In the rare instances where the two reviewers (GYHL and DCF) disagreed over the grading and inclusion of the studies, recourse to a third reviewer was made. Appropriate statistical analyses were applied (eg type of therapeutic effect measure, choice of fixed or random effects model, testing of heterogeneity, etc). The outcome measure was reported as relative hazard rate (RR) with 95% confidence interval (CI).
Results

Description of studies
A total of 2482 potentially relevant publications were initially identified and screened for retrieval: 1527 papers were excluded because of the coexistence of atrial fibrillation or generally lack of suitability of the study (see Quorum diagram, Figure 1 ). Finally, 946 studies were considered to be eligible for inclusion in this review, and in total 887 nonrandomised studies were excluded.
Among the studies evaluating NSAIDs (including aspirin), clopidogrel and ticlopidine, 33 studies were not included for further analysis because of the short duration of the studies and in 13 publications, we were unable to obtain data of the hypertensive subgroup; thus, nine potentially appropriate randomised controlled trials remained evaluating the effects of these drugs in hypertensive patients. One study was double reported, but two different definitions for hypertension were used: patients with SBP 4145 mmHg, 19 or patients treated with antihypertensive drugs at entry or during the trial. 20 Both sets of data reported on different aspects of antithrombotic therapy in hypertensive 35 and EMBASE 1998-2001 using an EMBASE RCT filter. 36 2. The NHS Database of Abstracts of Reviews of Effectiveness and any other relevant database were searched to identify eligible studies and review articles. Relevant foreign papers will be translated. 3. Abstracts from national and international hypertension meetings were studied to identify unpublished studies and relevant authors of these studies were contacted to obtain further details. 4. Searches of reference lists of papers were made (see Table 2 ). subgroups. These data were considered separately and duplicated data were not considered twice.
In three studies evaluating warfarin, detailed data on the hypertensive patients were not made available to us and had to be excluded. [21] [22] [23] One study remained for further analysis. 24 Five studies investigating ticlopidine and glycoprotein IIb/IIIa inhibitors and their impact on cardiovascular and haemorrhagic events lacked sufficient follow-up data. [25] [26] [27] [28] [29] A further publication was excluded due to the inability to acquire the relevant data. 30 Most of the excluded trials were less than 1-month duration; in particular, the five GPIIb/IIIa inhibitor trials were only observing the effects over a few days. We did not consider that this observational period would be sufficient to make any meaningful statements about the prevention of thromboembolic events in hypertensive patients. Furthermore, the NSAID trials assessed the effects on BP itself rather than thromboembolic complication.
Methodological quality of included studies
The only randomised placebo-controlled trial designed to investigate the effects of antithrombotic therapy (aspirin) on cardiovascular events and haemorrhagic complication in treated hypertensive patients was the large HOT study (Hypertension Optimal Treatment randomised trial 31 ). This trial was a primary prevention trial in patients with elevated BP (DBP between 100 and 115 mmHg). The aspirin component of this trial was a double-blind placebo-controlled design. Major cardiovascular events were defined as fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and other cardiovascular deaths. Silent myocardial infarction was defined as new Q or QS waves without clinical signs of myocardial infarction.
Among the other included studies, we tried to obtain further information from the authors. In the majority of the studies, we were unable to retrieve the data, which was largely due to the fact of the length of time since publication of the original trials. However, details were successfully requested from two studies 24, 32 and one study having published a subgroup analysis with a different definition hypertension (SBP4145 mmHg 19 ) than in the data set provided from the original trial. 20 Both sets of data have been considered separately. These trials are summarised in Table 2 . For the characteristics of the excluded studies of the Cochrane review, see Table 3 .
CAPRIE (Clopidogrel vs Aspirin in Patients at Risk of Ischaemic Events 32 ) was a secondary prevention trial in patients with recent ischaemic stroke, recent myocardial infarction (MI) or symptomatic peripheral arterial disease. End points were all-cause mortality, vascular death, myocardial infarction, ischaemic or haemorrhagic stroke, allcause rehospitalisation, hospitalisation for ischaemic events (unstable angina, TIA, limb ischaemic) or for bleeding events.
Huynh et al 24 reported a secondary prevention trial in patients with unstable angina or non-ST elevation MI and prior CABG. Patients with uncontrolled systemic hypertension (4180/95 mmHg) were excluded. Randomisation: warfarin (INR 2.0-2.5) þ placebo; aspirin 80 mg OD þ placebo; or warfarin þ aspirin; double-blind. Definition of end points: composite end point of all-cause mortality, MI or unstable angina requiring hospital admission. This study was underpowered by a low event rate to detect a difference between treatment groups.
The Thrombosis Prevention Trial 19,20 was a primary prevention trial in patients with high risk of ischaemic heart disease. Data for subgroup analysis of patients treated with antihypertensive medication at entry or during trial were reported in a subsequent publication. Definition of end points: fatal and nonfatal events (ie, coronary death and fatal and nonfatal myocardial infarction). Stroke was a secondary end point, with results for thrombotic and haemorrhagic events to be distinguished as far as possible.
Aspirin vs placebo (a) All-cause mortality All-cause mortality was reported in one trial (HOT). 31 In the HOT study, mortality was 3.0% in the aspirin-treated patients compared with 3.2% in the placebo-control group and was not different (P ¼ 0.36). The cardiovascular and noncardiovascular mortality, were also not different. Data relating to all cause mortality from Thrombosis Prevention Trial was not available. 20 (b) Cardiovascular events Cardiovascular events were evaluated in two studies. 20, 31 In the HOT trial, aspirin reduced MI (ARR ¼ 0.5%, NNT ¼ 200) and major cardiovascular events (ARR ¼ 0.57%, NNT ¼ 176) as compared to placebo. However, when all cardiovascular events including silent MI were considered, the reduction failed to reach statistical significance. Similarly, in the Thrombosis Prevention Trial, no significant difference was observed in the cardiovascular events in the hypertensive subgroup between the aspirin, 8.5% and placebo, 7.5%. 20 When the results of both studies were pooled for all cardiovascular events, there was no significant difference with aspirin as compared to placebo (OR 0.93; 95% CI: 0.82-1.06).
(c) Stroke
Ischaemic strokes were reported in two trials. 20, 31 In the pooled results, there was no significant difference between the aspirin and the control group (OR 0.94; 95% CI: 0.76-1.17).
(d) Haemorrhage
The haemorrhagic effects of aspirin alone when compared to placebo were evaluated in the HOT study. 31 There was a significant increase in major bleeds (ARI ¼ 0.65%, NNH ¼ 154) and minor bleeds (ARI ¼ 0.73%, NNH ¼ 137) with aspirin as compared to placebo. The differences in these events were mainly explained by increased gastrointestinal (72 vs 34 for major bleeds and 30 vs 18 for minor bleeds) and nasal bleeds (22 vs 12 for major bleeds and 66 vs 24 for minor bleeds) in the aspirin group. However, there was no significant difference in fatal haemorrhagic events (seven (aspirin) vs eight (placebo)).
Aspirin vs clopidogrel
The composite end point of stroke, MI or vascular death has been evaluated in one study in hypertensive patients was not different in patients taking aspirin, 12.1% as compared to clopidogrel, 11.0%. 32 Data on all-cause mortality, cardiovascular mortality, all cardiovascular events, stroke, myocardial infarction or haemorrhagic events were not reported. 
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Aspirin and/or warfarin
This study by Huynh et al 24 with a low event rate was underpowered to detect a difference in the hypertensive subgroup of patients. Data on all-cause mortality, cardiovascular mortality or all cardiovascular events were not reported. This study evaluated the effects of aspirin and warfarin alone or in combination on the composite end point of death and cardiovascular events (MI, stroke, angina, cardiac arrest and revascularisation procedures). There were no significant differences in this composite end point in the hypertensive subgroup (aspirin 2/14, warfarin 5/15, aspirin þ warfarin 5/14). There was no significant difference in the haemorrhagic complications (ASA, 0/14, warfarin, 0/15, aspirin þ warfarin, 1/14). 24 The single haemorrhagic event occurred in the group treated with aspirin and warfarin.
Warfarin vs no warfarin
In the Thrombosis Prevention Trial, 20 data on allcause mortality, cardiovascular mortality or all cardiovascular events were not reported.
(a) Coronary events Coronary events (coronary death, fatal and nonfatal myocardial infarction) were evaluated in one study comparing warfarin and warfarin plus aspirin (warfarin group) vs aspirin and placebo (no-warfarin group) in hypertensive patients. 20 Coronary events were not different in the warfarin group, 7.4 vs 8.6% in no-warfarin group. In the same study, the hypertensive subgroup was analysed according to the occurrence of strokes (excluding haemorrhagic strokes). Strokes were not different with warfarin (aspirin plus warfarin or warfarin alone), 2.8%, compared to no-warfarin group, 3.2%. Combined cardiovascular events (stroke and coronary events)
were not different between warfarin and no-warfarin groups.
(b) Haemorrhagic strokes Data for haemorrhagic strokes were only available in pooled form combining warfarin and aspirin compared to placebo. 20 No significant difference between the two arms was found. No haemorrhagic strokes occurred in the placebo group (N ¼ 342), but four such events were observed in the group taking warfarin and aspirin (N ¼ 338). Owing to the low event rate, no meaningful statistical analysis was possible.
Safety data
In patients of 60 years or older with isolated systolic hypertension (SBP4160-219 mmHg and DBPo95 mmHg, patients never taking NSAIDs (n ¼ 2882) were compared with patients on chronic NSAID intake (n ¼ 861), defined as reporting NSAID intake on at least 50% of the patient forms. 98 There was a tendency towards lower mortality (RR (95% CI), 0.77 (0.56-1.06)) and higher incidence of bleeding 1.13 (0.63-2.05) with chronic NSAID intake.
Discussion
Hypertension potentially confers a prothrombotic state. 6, 7, 10 Antithrombotic drugs such as aspirin, dipyridamole, clopidogrel, ticlopidine, GPIIb/IIIa inhibitors and oral anticoagulants may have a particular role in the treatment of hypertensive patients. This antithrombotic action might prevent death and/or cardiovascular thrombotic events. However, data from previous studies suggest that antithrombotic therapy is associated with an increase in haemorrhagic complications. This risk might be amplified in hypertensive patients, Antithrombotic therapy in hypertension DC Felmeden and GYH Lip potentially reversing the benefit/harm ratio for this therapy.
The primary analysis in the present review is based on four high-quality prospective randomised double-blind controlled trials. Two of these trials evaluated the effects of aspirin as compared to placebo, 20, 31 while one trial compared the effects of aspirin, warfarin and aspirin plus warfarin. 24 A further trial investigated the outcome of aspirin vs clopidogrel. 32 Currently, there is only one large RCT with antithrombotic therapy that recruited solely hypertensive patients. 31 Several of the potentially suitable trials enrolled up to 66% of patients with hypertension, but despite relentless efforts, we were unable to obtain the data for the subgroup of hypertensive patients. One large meta-analysis of prolonged antiplatelet therapy assessed outcome data in 142 trials in 'high-risk' patients (some vascular disease or other conditions implying an increased risk of occlusive vascular disease) and three trials in 'lowrisk' patients. 33 I was able to get data on the subgroup of hypertensive patients with DBP of 490 mmHg from 29 of these trials. They have reported these data on the composite outcome measure major vascular events (defined as nonfatal myocardial infarction, nonfatal stroke or vascular deaths). Unfortunately, it was not possible to get further information from the authors as to which trials were involved or the details of the data from the individual trials. Thus, these data could not be included in the present analysis. The Antiplatelet Trialists' Collaboration meta-analysis of prolonged antiplatelet therapy compared to placebo in 100 000 patients with or without hypertension reduced all-cause mortality (ARR ¼ 1.1%, NNT ¼ 91) which was mostly due to vascular deaths (ARR ¼ 1.0%, NNT ¼ 100); nonfatal myocardial infarction (ARR ¼ 1.1%, NNT ¼ 91); nonfatal stroke (ARR ¼ 0.5%, NNT ¼ 200); and the composite outcome measure major vascular events (ARR ¼ 2.4%, NNT ¼ 42). Haemorrhagic events were not reported. The benefit of antiplatelet therapy in secondary prevention in patients with or without hypertension has been established by the Antiplatelet Trialists' Collaboration meta-analysis.
In the hypertensive subgroup of 29 trials (10 600 patients), antiplatelet therapy significantly reduced major vascular events (ARR ¼ 4.1%, NNT ¼ 25). Allcause mortality, cardiovascular mortality, nonfatal MI, nonfatal stroke and haemorrhagic events were not reported in the hypertensive subgroup. These data suggest that the absolute benefit for antiplatelet therapy for secondary prevention is greater in patients with hypertension than in patients without hypertension.
The HOT trial demonstrated a significant reduction by aspirin as compared to placebo in major cardiovascular events (ARR ¼ 0.6%, NNT ¼ 176) and myocardial infarction (ARR ¼ 0.5%, NNT ¼ 200). 31 This benefit for primary prevention in hypertensive patients is substantially lower than that seen in the Antiplatelet Trialists' Collaboration analysis for secondary prevention. Furthermore, strokes, cardiovascular and all-cause mortality were not significantly different in the HOT trial. In particular, aspirin did not affect the stroke rate, and as not all patients had CT scans, the proportion of ischaemic and haemorrhagic strokes in HOT is uncertain. There was also a significant increase in major bleeds, ARI ¼ 0.7%, NNH ¼ 200) and minor bleeds, ARI ¼ 0.7%, NNH ¼ 137). The differences in these events were mainly explained by increased gastrointestinal (72 vs 34 for major bleeds and 30 vs 18 for minor bleeds) and nasal bleeds (22 vs 12 for major bleeds and 66 vs 24 for minor bleeds) in the aspirin vs placebo group. However, there was no significant difference in fatal haemorrhagic events (seven in the aspirin vs eight in placebo group). Since the magnitude of the harm is similar to the benefit, aspirin cannot be recommended for primary prevention in patients with hypertension.
The Antiplatelet Trialists' Collaboration metaanalysis of the three primary prevention trials based on 28 000 patients also showed no significant difference in all-cause mortality, nonfatal stroke or cardiovascular events. The significant decrease in nonfatal MI (ARR ¼ 0.5%, NNT ¼ 200) in antiplatelet group compared to placebo is similar to that seen in the HOT trial. Haemorrhagic events were not reported in the low-risk patient population.
Clopidogrel might be an alternative antithrombotic therapy to aspirin, although there has been no head-to-head of aspirin vs clopidogrel in hypertensive patients. The subgroup analysis of hypertensive patients only demonstrated a nonsignificant trend towards a decreased composite end point of stroke, MI or vascular death. 32 This would suggest that in hypertensive patients who are intolerant of aspirin that clopidogrel may be an effective alternative. However, further studies are required comparing clopidogrel and aspirin in hypertensive patients.
Rigorous and aggressive BP control is advisable when using antithrombotic therapy in hypertension, as suggested by the Thrombosis Prevention Trial. 20 A subgroup analysis from this trial showed that treatment with aspirin compared to placebo reduces major cardiovascular events particularly strokes in people with normal (SBP 130-145 mmHg) or even low BP (SBPo130 mmHg), whereas this risk reduction was not seen in patients with SBP 4145 mmHg. 19 This suggests that the benefit of aspirin therapy may occur primarily in patients with well-controlled BP.
There are only limited data available on warfarin as an antithrombotic agent in hypertension. Owing to small numbers, there was no significant difference in hypertensives when comparing warfarin with placebo or aspirin or the combination of aspirin and warfarin with regard to cardiovascular events or haemorrhagic complication. However, there is a nonsignificant trend suggesting that warfarin is inferior to aspirin in preventing thromboembolic events in this group. Warfarin seems to be also associated with a higher rate of haemorrhagic complications. Based on currently available data, warfarin therapy in hypertension cannot be recommended. There were no data available from subgroup analyses of hypertensive patients treated with glycoprotein IIb/IIIa inhibitors. However, oral glycoprotein IIb/IIIa inhibitors have failed to demonstrate an advantage over aspirin after percutaneous coronary revascularisation. 34 These patients are at high risk of thromboembolic events.
Conclusion
For primary prevention in hypertensive patients, antiplatelet therapy with aspirin cannot be recommended since the magnitude of benefit of a reduction in myocardial infarction is similar to the magnitude of harm of an increased risk of major haemorrhagic events. For secondary prevention in hypertensive patients, antiplatelet therapy is recommended, as the magnitude of the benefit is greater than that in a nonhypertensive population.
Antithrombotic therapy with warfarin alone or in combination with aspirin in patients with hypertension cannot be recommended because of lack of effectiveness in reducing cardiovascular events as well as a trend towards increased haemorrhagic events. Glycoprotein IIb/IIIa inhibitors as well as ticlopidine and clopidogrel have not been sufficiently evaluated in order to recommend their use in hypertensive patients.
As we have excluded patients with atrial fibrillation from this analyses, the recommendations do not apply to patients in atrial fibrillation with or without hypertension. This review adds to the Antiplatelet Trialists' Collaboration meta-analysis as we include the specific designed prospective placebo-controlled HOT trial with information on bleeding complications and correction of the estimated benefit on cardiovascular events of aspirin use in hypertension.
This review is also published in the Cochrane Database of Systematic Reviews, as follows: Lip GYH, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2004;(3):CD003186.
